The salient features of each approach are first discussed. The evolution of a set of regulatory and business conditions that seemed to favour one of these approaches to the detriment of the others are next examined; finally, the way in which recent developments in automation may have served to establish a new equilibrium between these three lead discovery systems is described.
Medicinal chemistry
Medicinal chemistry is the first of the modern drug discovery methods. It has given us many of the medicines available today. At its best medicinal chemistry combines a comprehensive knowledge of the medicinal chemistry, synthetic chemistry and pharmacology literature with the ability to imagine what no one else has imagined and then the drive to reduce the concept to synthetic practice. The best of the medicinal chemists also have the ability to think somewhere beyond three dimensions and are able to stretch analogous reasoning way beyond normal limits. A good example of medicinal chemistry is the program that led from Asperlicin (figure 1), a weak, fermentationderived cholecystokinin antagonist to an orally active compound (figure 2) 16000 times as potent [1] We cannot guarantee that the lead will necesssarily be useful but, then, no one else can make that promise either. 
